Q/C Technologies, Inc.
QCLS- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001321834
No open-market purchases or sales by Q/C Technologies, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $2.87M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Q/C Technologies, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Of which not filed for Q2 2026 | Q2 2026 | Change |
|---|---|---|---|---|
| Holders | 18 | 1 | 21 | +4 |
| Shares | 627.6K | 1.75K | 736.8K | +110.9K (+17.7%) |
| Value | $2.16M | $6.04K | $2.87M | +$714.6K (+33.1%) |
1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (6)
Institutions that held Q/C Technologies, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Balyasny Asset Management LLC | 57,692 | $225.0K | 0.00% |
| Northern Trust Corp | 17,997 | $70.2K | 0.00% |
| PEAK6 LLC | 12,778 | $49.8K | 0.00% |
| Barclays PLC | 950 | $3.71K | 0.00% |
| SBI Securities Co., Ltd. | 100 | $390 | 0.00% |
| Caitong International Asset Management Co., Ltd | 9 | $35 | 0.00% |
Sold out (2)
Institutions that held Q/C Technologies, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| BNP Paribas Arbitrage, SA | 300 | $1.03K |
| Royal Bank of Canada | 6 | $0 |
Not filed for Q2 2026 yet (1)
Institutions that held Q/C Technologies, Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Sunbelt Securities, Inc. | 1,750 | $6.04K |